Background Background Little is known aboutthe
Little is known aboutthe effect of pharmacotherapy in the effect of pharmacotherapy in the prevention of post-traumatic stress prevention of post-traumatic stress disorder (PTSD) relapse. disorder (PTSD) relapse.
Aims Aims To assess the efficacy and
To assess the efficacy and tolerability of fluoxetine in preventing tolerability of fluoxetine in preventing PTSD relapse. PTSD relapse.
Method Method This was a double-blind,
This was a double-blind, randomised, placebo-controlled study. randomised, placebo-controlled study. Following12 weeks of acute treatment, Following12 weeks of acute treatment, patients who responded were repatients who responded were rerandomised and continued in a 24-week randomised and continued in a 24-week relapse prevention phase with fluoxetine relapse prevention phase with fluoxetine ( (n n¼69) or placebo ( 69) or placebo (n n¼62).The primary 62).The primary efficacy assessment was the prevention of efficacy assessment was the prevention of PTSD relapse, based on the time to PTSD relapse, based on the time to relapse. relapse.
Results

Results Patients in the fluoxetine/
Patients in the fluoxetine/ fluoxetine group were less likely to relapse fluoxetine group were less likely to relapse than patients in the fluoxetine/placebo than patients in the fluoxetine/placebo group ( group (P P¼0.027).There were no clinically 0.027).There were no clinically significant differences in treatmentsignificant differences in treatmentemergent adverse events between emergent adverse events between treatment groups. treatment groups.
Conclusions Conclusions Fluoxetineis effective and
Fluoxetine is effective and well tolerated in the prevention of PTSD well tolerated in the prevention of PTSD relapse for up to 6 months. relapse for up to 6 months.
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Post-traumatic stress disorder (PTSD) is a Post-traumatic stress disorder (PTSD) is a psychopathological response to a terrifying psychopathological response to a terrifying experience. Initially associated with comexperience. Initially associated with combat, PTSD is observed in civilians bat, PTSD is observed in civilians following traumatic experiences, including following traumatic experiences, including violence, accident, natural disaster and violence, accident, natural disaster and life-threatening illness. Lifetime prevalence life-threatening illness. Lifetime prevalence of PTSD in civilians is between 1% and of PTSD in civilians is between 1% and 9% (Helzer 9% (Helzer et al et al, 1987; Breslau , 1987; Breslau et al et al, , 1991; Davidson 1991; Davidson et al et al, 1991) . Average dura-, 1991) . Average duration is 3 to 5 years, with many patients tion is 3 to 5 years, with many patients experiencing PTSD for more than 10 years experiencing PTSD for more than 10 years (Kessler (Kessler et al et al, 1995) . Selective serotonin re-, 1995). Selective serotonin reuptake inhibitors (SSRIs) such as sertraline, uptake inhibitors (SSRIs) such as sertraline, paroxetine and fluoxetine have shown effiparoxetine and fluoxetine have shown efficacy for up to 3 months in the treatment of cacy for up to 3 months in the treatment of PTSD (Connor PTSD (Connor et al et al, 1999; Brady , 1999; Brady et al et al, , 2000; Tucker 2000; Tucker et al et al, 2001; Martenyi , 2001; Martenyi et al et al, , 2002) . Sertraline has shown significant 2002). Sertraline has shown significant benefit during 24-to 28-week maintenance benefit during 24-to 28-week maintenance treatment of PTSD (Davidson treatment of PTSD (Davidson et al et al, 2001; , 2001; Londborg Londborg et al et al, 2001) . However, few pub-, 2001) . However, few published studies have examined the efficacy lished studies have examined the efficacy of pharmacotherapies in preventing PTSD of pharmacotherapies in preventing PTSD relapse, although considerable evidence relapse, although considerable evidence supports pharmacotherapeutic maintesupports pharmacotherapeutic maintenance treatment for major depression and nance treatment for major depression and anxiety, and panic disorders (Montgomery anxiety, and panic disorders (Montgomery et al et al, 1988; Frank , 1988; Frank et al et al, 1990; Entsuah , 1990; Entsuah et al et al, 1996; Reimherr , 1996; Reimherr et al et al, 1998; Michel-, 1998; Michelson son et al et al, 1999) . This study, conducted in , 1999). This study, conducted in Belgium, Bosnia, Croatia, Yugoslavia, Belgium, Bosnia, Croatia, Yugoslavia, Israel and South Africa, was designed to asIsrael and South Africa, was designed to assess the efficacy of fluoxetine in preventing sess the efficacy of fluoxetine in preventing PTSD relapse for up to 6 months. PTSD relapse for up to 6 months.
METHOD METHOD
Patient population Patient population
Participants were men and women aged Participants were men and women aged 18-65 years who met DSM-IV criteria for 18-65 years who met DSM-IV criteria for PTSD (American Psychiatric Association, PTSD (American Psychiatric Association, 1994) 420 at baseline were ineli-20 at baseline were ineligible for the study. Exclusion criteria gible for the study. Exclusion criteria included serious comorbid illness, concomiincluded serious comorbid illness, concomitant psychotherapy, serious suicidal risk or tant psychotherapy, serious suicidal risk or risk to others, and diagnosis of an Axis I risk to others, and diagnosis of an Axis I psychiatric disorder (defined by DSM-IV psychiatric disorder (defined by DSM-IV criteria) 5 years before the primary traucriteria) 5 years before the primary traumatic episode. Patients with lifetime matic episode. Patients with lifetime diagnoses of bipolar disorder, obsessivediagnoses of bipolar disorder, obsessivecompulsive disorder (OCD) or schizocompulsive disorder (OCD) or schizophrenia were excluded. Those with a phrenia were excluded. Those with a diagnosis of any Axis I psychiatric disorder diagnosis of any Axis I psychiatric disorder or comorbidity following the primary trauor comorbidity following the primary traumatic episode, except generalised anxiety matic episode, except generalised anxiety disorder, depression, panic disorder or sodisorder, depression, panic disorder or social phobia, were also excluded. Patients cial phobia, were also excluded. Patients with a history of alcohol or substance with a history of alcohol or substance misuse following the primary traumatic epimisuse following the primary traumatic episode were allowed to enrol if the misuse sode were allowed to enrol if the misuse had resolved at least 6 months before study had resolved at least 6 months before study entry. entry.
The study was conducted from June The study was conducted from June 1998 to August 2000 at 18 study centres 1998 to August 2000 at 18 study centres in Belgium, Bosnia, Croatia, Yugoslavia, in Belgium, Bosnia, Croatia, Yugoslavia, Israel and South Africa. The Israel and South Africa. The ethical review ethical review board for each site reviewed the study; board for each site reviewed the study; written informed consent was obtained written informed consent was obtained from all participants. from all participants.
Study design Study design
After a 1-to 2-week evaluation period, parAfter a 1-to 2-week evaluation period, participants were randomised to 12 weeks' ticipants were randomised to 12 weeks' double-blind acute treatment with fluoxedouble-blind acute treatment with fluoxetine or placebo. Fluoxetine-treated patients tine or placebo. Fluoxetine-treated patients initially received 20 mg/day. This dose initially received 20 mg/day. This dose could be increased by 20-mg increments at could be increased by 20-mg increments at each of three titration points based on preeach of three titration points based on predefined response criteria (CGI-S defined response criteria (CGI-S5 53) to a 3) to a maximum dosage of 80 mg/day. Acute remaximum dosage of 80 mg/day. Acute response to fluoxetine sponse to fluoxetine v.
v. placebo has been placebo has been described elsewhere (Martenyi described elsewhere (Martenyi et al et al, 2002) . , 2002). After 12 weeks of acute treatment with After 12 weeks of acute treatment with fluoxetine or placebo, participants who refluoxetine or placebo, participants who responded to treatment by a 50% decrease sponded to treatment by a 50% decrease in the eight-item Treatment Outcome PTSD in the eight-item Treatment Outcome PTSD (TOP-8) score (Davidson & Colket, 1997) (TOP-8) score (Davidson & Colket, 1997) from baseline, a CGI-S score from baseline, a CGI-S score 4 42, and fail-2, and failing DSM-IV diagnostic criteria for PTSD ing DSM-IV diagnostic criteria for PTSD continued in a 24-week relapse prevention continued in a 24-week relapse prevention phase. Those patients who had received phase. Those patients who had received fluoxetine were randomised either to fluoxetine were randomised either to Patients who responded to treatment Patients who responded to treatment with placebo during the acute treatment with placebo during the acute treatment phase were continued on placebo during phase were continued on placebo during the relapse prevention phase to preserve the relapse prevention phase to preserve blinding. Participants discontinued the trial blinding. Participants discontinued the trial if relapse criteria were met (40% increase in if relapse criteria were met (40% increase in TOP-8 score and an increase in CGI-S TOP-8 score and an increase in CGI-S score of score of 5 52 from the baseline at week 12 2 from the baseline at week 12 of acute treatment) at any time during of acute treatment) at any time during the relapse prevention phase. Relapse the relapse prevention phase. Relapse could also be determined by the clinical could also be determined by the clinical judgement of the investigator. judgement of the investigator.
Outcome measures Outcome measures
The primary efficacy measure for the reThe primary efficacy measure for the relapse prevention phase was time to relapse lapse prevention phase was time to relapse based on the TOP-8 scale and the CGI-S based on the TOP-8 scale and the CGI-S scale. TOP-8 is an 8-item clinician-rated scale. TOP-8 is an 8-item clinician-rated instrument measuring the presence and seinstrument measuring the presence and severity of PTSD symptoms in three major verity of PTSD symptoms in three major dimensions (intrusive, avoidant and hyperdimensions (intrusive, avoidant and hyperarousal symptoms). Each item is rated from arousal symptoms). Each item is rated from 0 to 4, with higher numbers indicating 0 to 4, with higher numbers indicating greater severity. greater severity.
Secondary assessments included the Secondary assessments included the CAPS-DX total, intrusive, avoidance and CAPS-DX total, intrusive, avoidance and hyperarousal scores; the Clinical Global hyperarousal scores; the Clinical Global Impression of Improvement (CGI-I) scale Impression of Improvement (CGI-I) scale (Guy, 1976) ; and the Davidson Trauma (Guy, 1976) ; and the Davidson Trauma Scale (DTS) total, intrusive, avoidance and Scale (DTS) total, intrusive, avoidance and hyperarousal sub-scores (Davidson hyperarousal sub-scores (Davidson et al et al, , 1997) . Changes in comorbid psychiatric 1997). Changes in comorbid psychiatric disorders were measured using the disorders were measured using the MADRS, the Hamilton Rating Scale for MADRS, the Hamilton Rating Scale for Anxiety (HRSA; Hamilton, 1959) Derogatis, 1983; Rief & Fichter, 1992) . Both the DTS and the & Fichter, 1992). Both the DTS and the SCL-90-R are patient-rated scales; all SCL-90-R are patient-rated scales; all others are clinician-rated. others are clinician-rated.
Safety was assessed by evaluating Safety was assessed by evaluating treatment-emergent adverse events, discontreatment-emergent adverse events, discontinuations for adverse events, vital signs tinuations for adverse events, vital signs measurements and clinical laboratory tests. measurements and clinical laboratory tests. Adverse events were ascertained by nonAdverse events were ascertained by nonprobing enquiry and were recorded regardprobing enquiry and were recorded regardless of perceived causality. An event was less of perceived causality. An event was considered treatment-emergent if it occonsidered treatment-emergent if it occurred for the first time or worsened curred for the first time or worsened during the relapse prevention phase of the during the relapse prevention phase of the study. Investigators assessed patient comstudy. Investigators assessed patient compliance at each visit by direct questioning pliance at each visit by direct questioning and by counting returned medication. and by counting returned medication. Patients were considered non-compliant if Patients were considered non-compliant if they missed more than 4 consecutive days they missed more than 4 consecutive days or more than 10 cumulative days of study or more than 10 cumulative days of study medication. Patients were also considered medication. Patients were also considered non-compliant if the ratio of the number non-compliant if the ratio of the number of capsules taken to the number of capof capsules taken to the number of capsules prescribed was less than 0.8 or more sules prescribed was less than 0.8 or more than 1.2. than 1.2.
Statistical methods Statistical methods
Time to relapse was evaluated by plotting Time to relapse was evaluated by plotting Kaplan-Meier survival curves. A log-rank Kaplan-Meier survival curves. A log-rank test was used to compare the time to relapse test was used to compare the time to relapse curves for the fluoxetine/fluoxetine and curves for the fluoxetine/fluoxetine and fluoxetine/placebo treatment groups. Anafluoxetine/placebo treatment groups. Analyses of change from baseline (week 12 of lyses of change from baseline (week 12 of acute treatment) in TOP-8, MADRS, acute treatment) in TOP-8, MADRS, DTS, SCI-90-R, CGI-S and HRSA scores DTS, SCI-90-R, CGI-S and HRSA scores were conducted using a repeated-measures were conducted using a repeated-measures model with visit, treatment, investigator model with visit, treatment, investigator and visit-by-treatment interaction as effects and visit-by-treatment interaction as effects in the model. The corresponding baseline in the model. The corresponding baseline score was included in the model as a covariscore was included in the model as a covariate. An unstructured covariance matrix was ate. An unstructured covariance matrix was fitted to the within-patient repeated fitted to the within-patient repeated measures. Change from baseline to each measures. Change from baseline to each visit was tested between treatment groups visit was tested between treatment groups using contrasts within the repeatedusing contrasts within the repeatedmeasures model. The comparison between measures model. The comparison between groups of the difference from baseline to groups of the difference from baseline to the last visit (week 36) was considered the the last visit (week 36) was considered the primary comparison. Analysis of CGI-I primary comparison. Analysis of CGI-I was done in a similar manner using raw was done in a similar manner using raw post-baseline values. For the CAPS total post-baseline values. For the CAPS total scores and sub-scores, which were collected scores and sub-scores, which were collected at baseline (week 12), mid-point (week 24) at baseline (week 12), mid-point (week 24) and end-point (week 36 or discontinuaand end-point (week 36 or discontinuation), analyses of the change from baseline tion), analyses of the change from baseline to end-point (last observation carried to end-point (last observation carried forward, LOCF) were conducted using forward, LOCF) were conducted using analysis of variance with treatment and analysis of variance with treatment and investigator as effects in the model. investigator as effects in the model.
To investigate the possible effect of To investigate the possible effect of trauma type (combat-related trauma type (combat-related v.
v. nonnoncombat-related trauma), a repeatedcombat-related trauma), a repeatedmeasures analysis of variance was measures analysis of variance was conducted as described above, with the conducted as described above, with the addition of trauma type in the model. In addition of trauma type in the model. In addition, the two-way interactions of addition, the two-way interactions of trauma type by visit and by treatment were trauma type by visit and by treatment were included along with the three-way interincluded along with the three-way interaction of treatment by trauma type and by action of treatment by trauma type and by visit. visit.
Treatment differences in patient characTreatment differences in patient characteristics at baseline were assessed using teristics at baseline were assessed using All analyses were based upon the All analyses were based upon the intent-to-treat principle and were perintent-to-treat principle and were performed using SAS software (SAS Institute formed using SAS software (SAS Institute Inc., Version 6 (for MVS), Carey, NC, Inc., Version 6 (for MVS), Carey, NC, 1991). Tests of treatment effects were 1991). Tests of treatment effects were conducted at a two-sided alpha level of conducted at a two-sided alpha level of 0.05. Investigators with fewer than two ran-0.05. Investigators with fewer than two randomised patients per treatment group were domised patients per treatment group were pooled for statistical analysis purposes. pooled for statistical analysis purposes.
RESULTS RESULTS
Sample description Sample description
Participants were predominantly male Participants were predominantly male (81%) and Caucasian (90%); 47% had (81%) and Caucasian (90%); 47% had been exposed to combat-related traumatic been exposed to combat-related traumatic events. None reported onset of PTSD at a events. None reported onset of PTSD at a young age or childhood sexual abuse. Of young age or childhood sexual abuse. Of the 226 participants randomised to fluoxethe 226 participants randomised to fluoxetine during the 12-week acute treatment tine during the 12-week acute treatment phase, 131 responders to treatment agreed phase, 131 responders to treatment agreed to continue in the study. Of these, 69 were to continue in the study. Of these, 69 were randomised to receive fluoxetine and 62 to randomised to receive fluoxetine and 62 to receive placebo in the 24-week relapse prereceive placebo in the 24-week relapse prevention phase (Fig. 1) . Demographic as vention phase (Fig. 1) . Demographic as well as disease characteristics following 12 well as disease characteristics following 12 weeks of acute fluoxetine treatment were weeks of acute fluoxetine treatment were similar in both groups (Table 1) . Of the similar in both groups (Table 1) . Of the 75 participants assigned to placebo in the 75 participants assigned to placebo in the acute phase, 31 were responders and conacute phase, 31 were responders and continued on placebo during the 24-week tinued on placebo during the 24-week relapse prevention phase. relapse prevention phase.
Medication compliance was high for Medication compliance was high for both groups at all time points. The mean both groups at all time points. The mean exposure to the study drug was 157 days exposure to the study drug was 157 days during the 6-month relapse prevention during the 6-month relapse prevention phase for fluoxetine/fluoxetine-treated paphase for fluoxetine/fluoxetine-treated patients. The mean final dose was 53 mg/day. tients. The mean final dose was 53 mg/day.
Efficacy Efficacy
An analysis of time to relapse showed that An analysis of time to relapse showed that fluoxetine was statistically significantly fluoxetine was statistically significantly superior to placebo in relapse prevention superior to placebo in relapse prevention (log-rank (log-rank w w 2 2 ¼4.88, 4.88, P P¼0.027) (Fig. 2) . 0.027) (Fig. 2) . A higher percentage of fluoxetine/ A higher percentage of fluoxetine/ fluoxetine-treated patients (82.6%) comfluoxetine-treated patients (82.6%) completed the relapse prevention phase completed the relapse prevention phase compared with fluoxetine/placebo-treated pared with fluoxetine/placebo-treated patients (66.1%) (Fisher's exact test, patients (66.1%) (Fisher's exact test, P P¼0.043). A higher percentage of 0.043). A higher percentage of fluoxetine/placebo-treated patients (16.1%) fluoxetine/placebo-treated patients (16.1%) discontinued the study because of relapse discontinued the study because of relapse compared with fluoxetine/fluoxetine-treated compared with fluoxetine/fluoxetine-treated patients (5.8%) ( patients (5.8%) (P P¼0.087) ( Table 2) . 0.087) ( Table 2 ). Fluoxetine/fluoxetine-treated patients Fluoxetine/fluoxetine-treated patients had statistically significantly greater mean had statistically significantly greater mean improvement in TOP-8 total score from improvement in TOP-8 total score from baseline to end-point than did fluoxetine/ baseline to end-point than did fluoxetine/ placebo-treated patients (fluoxetine/fluoxeplacebo-treated patients (fluoxetine/fluoxetine, tine, 7 71.8; fluoxetine/placebo +0.05; 1.8; fluoxetine/placebo +0.05; F F¼6.72 6.72 1,112 1,112 , , P P¼0.011) (Fig. 3) . The effect 0.011) (Fig. 3) . The effect size of 0.5, typically considered to be of size of 0.5, typically considered to be of medium size, implies that the median medium size, implies that the median improvement in the fluoxetine/fluoxetine improvement in the fluoxetine/fluoxetine group exceeded the improvement of 69% group exceeded the improvement of 69% of individuals in the fluoxetine/placebo of individuals in the fluoxetine/placebo group. group.
The CGI-S scores also showed statistiThe CGI-S scores also showed statistically significant improvement for fluoxecally significant improvement for fluoxetine/fluoxetine-treated patients compared tine/fluoxetine-treated patients compared with fluoxetine/placebo-treated patients with fluoxetine/placebo-treated patients ( (F F¼8.39 8.39 1,112 1,112 , , P P¼0.005) ( Table 3 ). In addi-0.005) ( Table 3 ). In addition, fluoxetine-treated patients experition, fluoxetine-treated patients experienced greater improvement in CAPS score enced greater improvement in CAPS score compared with placebo-treated patients. compared with placebo-treated patients. The difference between the two treatment The difference between the two treatment groups was statistically significant for groups was statistically significant for the avoidance sub-score ( the avoidance sub-score (F F¼5.44 5.44 1,113 1,113 , , P P¼0.021) but was not statistically signi-0.021) but was not statistically significant for the CAPS total score or the CAPS ficant for the CAPS total score or the CAPS intrusive sub-score (total score: intrusive sub-score (total score: F F¼3.80 3.80 1,113 1,113 , , P P¼0.054; intrusive: 0.054; intrusive: F F¼3.11 3.11 1,113 1,113 , , P P¼0.080). 0.080). The patient-rated SCL-90-R and DTS did The patient-rated SCL-90-R and DTS did not show statistically significant separanot show statistically significant separations between treatment groups in total tions between treatment groups in total scores or any DTS scores or any DTS sub-scores (Table 3) .
sub-scores (Table 3 ). Fluoxetine/fluoxetineFluoxetine/fluoxetine-treated patients extreated patients experienced significantly greater improveperienced significantly greater improvement compared with fluoxetine/placeboment compared with fluoxetine/placebotreated patients in symptoms of anxiety treated patients in symptoms of anxiety and depression as measured by the HRSA and depression as measured by the HRSA ( (F F¼6.73 6.73 1, 112 1,112 , , P P¼0.011) and MADRS 0.011) and MADRS ( (F F¼5.13 5.13 1, 112 1,112 , , P P¼0.026) scores (Table 3) . 0.026) scores (Table 3) . When exploring the possible effect of When exploring the possible effect of trauma type (combat-related trauma type (combat-related v.
v. nonnoncombat-related), a significant three-way combat-related), a significant three-way interaction was detected between visit, interaction was detected between visit, treatment and trauma type ( treatment and trauma type (P P¼0.005). For 0.005). For the non-combat-related traumas, the mean the non-combat-related traumas, the mean change from baseline to last visit was change from baseline to last visit was 7 71.72 for the fluoxetine/fluoxetine group 1.72 for the fluoxetine/fluoxetine group compared with compared with 7 71.25 for the fluoxetine/ 1.25 for the fluoxetine/ placebo group ( placebo group (P P¼0.633). For the 0.633). For the combat-related traumas, the mean change combat-related traumas, the mean change for the fluoxetine/fluoxetine group was for the fluoxetine/fluoxetine group was 7 71.62 compared with +1.97 for the 1.62 compared with +1.97 for the fluoxetine/placebo group ( fluoxetine/placebo group (P P¼0.002). It 0.002). It should be noted that for patients with should be noted that for patients with non-combat-related PTSD, placebo was non-combat-related PTSD, placebo was associated with some improvement but associated with some improvement but for patients with combat-related PTSD, for patients with combat-related PTSD, placebo was associated with a worsening placebo was associated with a worsening of symptoms. Fluoxetine was associated of symptoms. Fluoxetine was associated with similar levels of improvement in both with similar levels of improvement in both patient types. patient types.
Safety Safety
There were no significant differences There were no significant differences between the two groups in any vital sign between the two groups in any vital sign measure or laboratory result. measure or laboratory result.
The difference between treatment The difference between treatment groups in the number of patients reporting groups in the number of patients reporting one or more treatment-emergent adverse one or more treatment-emergent adverse events was not statistically significant events was not statistically significant (fluoxetine/fluoxetine 39%; fluoxetine/pla-(fluoxetine/fluoxetine 39%; fluoxetine/placebo 24%; Fisher's exact test cebo 24%; Fisher's exact test P P¼0.091). 0.091). There were no statistically significant difThere were no statistically significant differences in the numbers of patients reportferences in the numbers of patients reporting any single event. The adverse events ing any single event. The adverse events most commonly reported by fluoxetine/ most commonly reported by fluoxetine/ fluoxetine-treated patients were insomnia fluoxetine-treated patients were insomnia (15%), anxiety (6%) and headache (6%); (15%), anxiety (6%) and headache (6%); those most commonly reported by fluoxethose most commonly reported by fluoxetine/placebo-treated patients were insomnia tine/placebo-treated patients were insomnia (10%), headache (5%) and pain (5%). Two (10%), headache (5%) and pain (5%). Two patients, both in the fluoxetine/fluoxetine patients, both in the fluoxetine/fluoxetine treatment group, experienced serious adtreatment group, experienced serious adverse events requiring hospitalisation (back verse events requiring hospitalisation (back pain and traffic accident). Only the patient pain and traffic accident). Only the patient involved in the traffic accident discontinued involved in the traffic accident discontinued the trial early. the trial early.
DISCUSSION DISCUSSION Efficacy Efficacy
Fluoxetine treatment for maintenance of Fluoxetine treatment for maintenance of improvement of PTSD symptoms is assoimprovement of PTSD symptoms is associated with significantly longer time to ciated with significantly longer time to relapse, greater improvement in overall relapse, greater improvement in overall PTSD symptoms and significantly greater PTSD symptoms and significantly greater reduction in symptoms of comorbid disorreduction in symptoms of comorbid disorders than is placebo treatment. There apders than is placebo treatment. There appears to be a delay between cessation of pears to be a delay between cessation of active treatment and worsening of sympactive treatment and worsening of symptoms; clinicians should be aware of the toms; clinicians should be aware of the possibility of a relapse of symptoms in papossibility of a relapse of symptoms in patients for a period of several months after tients for a period of several months after the discontinuation of fluoxetine treatment. the discontinuation of fluoxetine treatment. Participants in the fluoxetine/fluoxetine Participants in the fluoxetine/fluoxetine treatment group continued to experience treatment group continued to experience statistically significant improvement in statistically significant improvement in mean TOP-8 score throughout the 24-mean TOP-8 score throughout the 24-week relapse prevention period and showed week relapse prevention period and showed statistically significant better improvement statistically significant better improvement at end-point than did fluoxetine/placeboat end-point than did fluoxetine/placebotreated participants. treated participants.
Improvement in illness severity, as Improvement in illness severity, as demonstrated by the CGI-S scale, was demonstrated by the CGI-S scale, was also statistically significant ( also statistically significant (P P¼0.005). 0.005).
Fluoxetine/fluoxetine-treated participFluoxetine/fluoxetine-treated participants experienced significantly greater ants experienced significantly greater improvement compared with fluoxetine/ improvement compared with fluoxetine/ placebo-treated participants in the CAPS placebo-treated participants in the CAPS avoidance sub-score. Both of the patientavoidance sub-score. Both of the patientrated scales (DTS and SCL-90-R) failed rated scales (DTS and SCL-90-R) failed to show significant differences in the to show significant differences in the improvement of PTSD symptoms between improvement of PTSD symptoms between the two treatment groups, possibly as a the two treatment groups, possibly as a result of inconsistent patient self-rating. result of inconsistent patient self-rating.
Because comorbid psychiatric disorders Because comorbid psychiatric disorders such as anxiety and depression are comsuch as anxiety and depression are commonly associated with PTSD, the HRSA monly associated with PTSD, the HRSA and MADRS scores were collected throughand MADRS scores were collected throughout the relapse prevention phase to monitor out the relapse prevention phase to monitor changes in patients' comorbid symptoms. changes in patients' comorbid symptoms. When compared with fluoxetine/placeboWhen compared with fluoxetine/placebotreated participants, fluoxetine/fluoxetinetreated participants, fluoxetine/fluoxetinetreated participants experienced significantly treated participants experienced significantly greater improvement in both HRSA and greater improvement in both HRSA and MADRS total scores. MADRS total scores.
The findings demonstrate the efficacy The findings demonstrate the efficacy of pharmacotherapy with fluoxetine, an of pharmacotherapy with fluoxetine, an SSRI, in the prevention of PTSD relapse SSRI, in the prevention of PTSD relapse and continual improvement in PTSD and continual improvement in PTSD symptoms for up to 6 months following symptoms for up to 6 months following response to 12 weeks of acute treatment. response to 12 weeks of acute treatment. In addition, the study design excluded In addition, the study design excluded patients with comorbid major depression patients with comorbid major depression (patients with a MADRS score (patients with a MADRS score 4 420 were 20 were excluded), which differs from previous excluded), which differs from previous studies that allowed unlimited severity of studies that allowed unlimited severity of ). The results of this study, therefore, represent improvement study, therefore, represent improvement and relapse prevention of PTSD rather and relapse prevention of PTSD rather than improvement and relapse prevention than improvement and relapse prevention of a mixed state of PTSD and depression. of a mixed state of PTSD and depression.
Safety Safety
Safety and tolerability of fluoxetine in this Safety and tolerability of fluoxetine in this study were comparable to previous studies study were comparable to previous studies of fluoxetine in PTSD and to fluoxetine of fluoxetine in PTSD and to fluoxetine trials for other indications. Fluoxetine was trials for other indications. Fluoxetine was generally well tolerated, with no statistigenerally well tolerated, with no statistically significant differences between treatcally significant differences between treatment groups in either the incidence of any ment groups in either the incidence of any individual adverse event, or the drop-out individual adverse event, or the drop-out rate due to adverse events. rate due to adverse events.
The mean fluoxetine dose at end-point, The mean fluoxetine dose at end-point, 53 mg/day, was consistent with fluoxetine 53 mg/day, was consistent with fluoxetine doses in the upper range for the treatment doses in the upper range for the treatment of clinical depression and the recommended of clinical depression and the recommended range for patients with OCD. range for patients with OCD. Table 2  Table 2 Reasons for discontinuation Reasons for discontinuation Fluoxetine/fluoxetine ( Fluoxetine/fluoxetine (n n¼69) 69)
Fluoxetine/placebo ( Fluoxetine/placebo (n n¼62) 62) n n (%) (%) This study was designed to assess the This study was designed to assess the effect of pharmacotherapy with fluoxetine effect of pharmacotherapy with fluoxetine for preventing PTSD relapse, and investifor preventing PTSD relapse, and investigators were instructed to avoid providing gators were instructed to avoid providing any type of counselling or behavioural any type of counselling or behavioural therapy to study participants during therapy to study participants during study visits. Numerous other studies, study visits. Numerous other studies, however, have shown that psychotherapy however, have shown that psychotherapy is effective in the treatment of individuals is effective in the treatment of individuals with PTSD, and various behavioural with PTSD, and various behavioural treatments have shown efficacy in the treatments have shown efficacy in the reduction of the core symptoms of PTSD reduction of the core symptoms of PTSD (Ballenger, 1999) . Results of the acute (Ballenger, 1999) . Results of the acute treatment phase of this trial show an intreatment phase of this trial show an increased placebo response for participants creased placebo response for participants with dissociative symptoms at baseline, with dissociative symptoms at baseline, resulting in a statistically significant interresulting in a statistically significant interaction between treatment group and action between treatment group and participants with and without dissociative participants with and without dissociative symptoms at baseline (Martenyi symptoms at baseline (Martenyi et al et al, , 2002 ). These results suggest that different 2002). These results suggest that different populations of individuals with PTSD populations of individuals with PTSD may respond favourably to psychotherapy may respond favourably to psychotherapy compared with pharmacotherapy. Indeed, compared with pharmacotherapy. Indeed, the combination of psychotherapy and the combination of psychotherapy and pharmacotherapy may yield the most pharmacotherapy may yield the most significant therapeutic effect and warrants significant therapeutic effect and warrants further study. further study.
One limitation of this study was the One limitation of this study was the duration of acute therapy. Both large duration of acute therapy. Both large national surveys (Kessler national surveys (Kessler et al et al, 1995) and , 1995) and a pharmacotherapy study with sertraline a pharmacotherapy study with sertraline (Davidson (Davidson et al et al, 2001) suggest that PTSD , 2001) suggest that PTSD may require a fairly lengthy acute treatment may require a fairly lengthy acute treatment (in excess of 12 weeks) before maximum (in excess of 12 weeks) before maximum improvement of symptoms is achieved. In improvement of symptoms is achieved. In this study, the statistically significant conthis study, the statistically significant continued improvement in PTSD symptoms tinued improvement in PTSD symptoms (measured by the TOP-8 scale) after 12 (measured by the TOP-8 scale) after 12 weeks of acute therapy suggests that the full weeks of acute therapy suggests that the full therapeutic effect of fluoxetine on the therapeutic effect of fluoxetine on the improvement of PTSD symptoms may not improvement of PTSD symptoms may not have been observed even after 9 months have been observed even after 9 months of therapy. of therapy. Unlike previous studies of selective serotonin reuptake inhibitors and posttraumatic stress disorder (PTSD), this study focused on improvement and relapse traumatic stress disorder (PTSD), this study focused on improvement and relapse prevention of PTSD rather than improvement and relapse prevention of a mixed state prevention of PTSD rather than improvement and relapse prevention of a mixed state of PTSD and depression. of PTSD and depression. Optimal length of acute treatment of PTSD exceeds 3 months; current data suggest improvement continues for up to 9 months or more. suggest improvement continues for up to 9 months or more.
LIMITATIONS LIMITATIONS
& & PTSD symptoms continued to improve during the relapse prevention period of this PTSD symptoms continued to improve during the relapse prevention period of this study, suggesting that a longer acute treatment phase should have been used before study, suggesting that a longer acute treatment phase should have been used before initiating the relapse prevention phase. initiating the relapse prevention phase. This study demonstrated the efficacy of fluoxetine for relapse prevention for up to 6 months of treatment. However, PTSD is a chronic condition and studies of therapy 6 months of treatment. However, PTSD is a chronic condition and studies of therapy over longer periods are needed. over longer periods are needed.
